Rezum vs TURP vs UroLift Comparison – Which Minimally Invasive BPH Treatment Is Right for You?

Men researching surgical alternatives to lifelong BPH medications frequently search Google for a head-to-head Rezum vs TURP vs UroLift comparison. While Transurethral Resection of the Prostate (TURP) has historically served as the endoscopic surgical standard, Minimally Invasive Surgical Therapies (MISTs)—specifically Rezum Water Vapor Thermal Therapy and Prostatic Urethral Lift (UroLift)—now allow men to achieve durable urinary relief without general anesthesia or high rates of retrograde ejaculation [1, 2].

💡 Quick Clinical Summary:
In an evidence-based Rezum vs TURP vs UroLift comparison: TURP mechanically cuts away prostate tissue (delivering immediate high flow rates but carrying a 65%–75% risk of retrograde ejaculation and 3–5 days of hospitalization); UroLift pins the lateral lobes open using permanent metallic implants (avoiding tissue ablation but leaving foreign bodies in the prostate and carrying a 13.6% five-year surgical retreatment rate); whereas Rezum uses sterile water vapor to naturally ablate both lateral and obstructive median lobes without permanent implants, achieving a 4.4% five-year surgical retreatment rate and preserving antegrade ejaculation in 95%–97% of patients [1, 2, 3].

Figure 1: Unlike UroLift (which leaves permanent metal clips) or TURP (which resects the bladder neck), Rezum uses convective water vapor to ablate hyperplastic tissue within natural anatomical boundaries (Source: Journal of Clinical Medicine / NCBI PMC).

1. Anatomical & Mechanical Differences – Tissue Resection vs Mechanical Pinning vs Convective Vapor Ablation

Not all minimally invasive prostate procedures treat the underlying hyperplasia in the same way.

Understanding how each modality interacts with prostatic anatomy is essential for selecting the right intervention:

• Transurethral Resection of the Prostate (Bipolar TURP): Uses an electrified wire loop to cut away hyperplastic transition zone tissue and the internal bladder neck sphincter. While highly effective at relieving bladder outlet obstruction immediately, resecting the bladder neck causes seminal fluid to pass backward into the bladder during orgasm (retrograde ejaculation) in up to three-quarters of patients [2].
• Prostatic Urethral Lift (PUL / UroLift): Deploys permanent nitinol and stainless-steel suture implants to mechanically compress the lateral prostatic lobes outward, much like tying back window curtains. Because UroLift does not remove or destroy hyperplastic cells, prostate tissue can continue to grow around the implants over time, and permanent metallic clips can create image artifacts on future multiparametric prostate MRI scans (mpMRI) used for prostate cancer screening [2, 3].
• Rezum Water Vapor Thermal Therapy: Injects sterile water vapor for 9 seconds per site into the hyperplastic tissue. The steam condenses and causes coagulative cell death, allowing the body to naturally absorb the treated tissue over 6 to 12 weeks. Crucially, Rezum leaves zero permanent metallic implants behind and directly ablates obstructive median lobes (intravesical prostatic protrusion) [1, 3].

2. Head-to-Head Clinical Comparison Table – Rezum vs UroLift vs Bipolar TURP

Based on the American Urological Association (AUA) BPH Guidelines and 5-year pivotal trials (Rezūm II Study vs LIFT Study), Dr. Dang Phuoc Dat summarizes the key clinical differentiators below [1, 2, 3]:

Figure 2: Rezum shrinks obstructive prostate tissue naturally over 6 to 12 weeks, creating a wide prostatic channel without leaving metallic implants behind.

3. Why Median Lobe Capability and MRI Compatibility Make Rezum the Preferred MIST

Preserving future diagnostic clarity for prostate cancer screening is just as important as relieving urinary symptoms.

Approximately 30% of men seeking BPH intervention have an enlarged median lobe protruding into the bladder neck [1]. In the 5-year Rezūm II trial analysis, McVary et al. specifically noted that Rezum's 4.4% surgical retreatment rate was more than three times lower than the 13.6% retreatment rate reported in the 5-year UroLift LIFT trial [1, 3]. Furthermore, because men over 55 require lifelong vigilance for prostate cancer via PSA monitoring and multiparametric MRI (mpMRI), Rezum offers a distinct oncological advantage: once the treated tissue is absorbed, the prostate contains no metallic clips that could create susceptibility artifacts on T2-weighted or diffusion-weighted MRI sequences [3].

4. Frequently Asked Questions (FAQ)

Question 1: Why does UroLift have a higher 5-year retreatment rate (13.6%) than Rezum (4.4%)?

Because UroLift only compresses tissue mechanically without destroying hyperplastic cells, ongoing stromal and glandular proliferation can eventually overcome the tension of the suture implants. Rezum physically ablates the hyperplastic tissue within the transition and central zones, resulting in true volumetric tissue reduction [1, 3].

Question 2: Is the 3-to-5-day catheter after Rezum worth the trade-off compared to UroLift?

For the vast majority of patients, wearing a soft silicone catheter with a discreet leg bag for 3 to 5 days is a minor, temporary inconvenience in exchange for leaving zero metal implants inside the prostate, effectively treating a median lobe, and achieving a three-fold lower 5-year surgical retreatment rate [1, 3].

Question 3: Which BPH procedures are performed by Dr. Dang Phuoc Dat in Da Nang?

At Family Hospital Da Nang, Dr. Dang Phuoc Dat performs the full spectrum of modern endourological BPH interventions—including Rezum Water Vapor Therapy, Bipolar TURP, and Laser Prostate Enucleation (HoLEP)—ensuring unbiased, anatomy-tailored recommendations for every patient.

5. References (Vancouver Style)

1. McVary KT, Gittelman MC, Goldberg KA, Patel K, Shore ND, Levin RM, et al. Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urol. 2021;206(3):715-24.
2. Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2024;211(1):11-9.
3. Miller LE, Chughtai B, Dornbier RA, McVary KT. Surgical Reintervention Rate after Prostatic Urethral Lift vs Water Vapor Thermal Therapy: A Systematic Review and Meta-Analysis. J Urol. 2020;204(4):645-52.
4. Gravas S, Gacci M, Gratzke C, Herrmann TRW, Karavitakis M, Kyriazis I, et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS). Arnhem: European Association of Urology; 2025-2026.

Medical Disclaimer: This clinical article is authored and medically reviewed by Dr. Dang Phuoc Dat, MD, Specialist Level I (Bs CKI Đặng Phước Đạt) based on current international urological guidelines for educational purposes. It does not substitute for an in-person clinical examination, diagnostic imaging, and individualized treatment plan from a qualified urologist.